Abstract 2137
Background
The management of papillary thyroid carcinoma (PTC) should be decided by Risk-adapted approach. However, intermediated risk PTC needs to be stratified more precisely. Otherwise, the utility of 18F-FDG PET images in patients with PTC is restrictive. The aim of this study was to investigate the prognostic value of Metabolic Tumor Volume (MTV) measured on 18F-FDG PET images in patients with papillary thyroid carcinoma treated with surgery.
Methods
We retrospectively analyzed 102 patients with PTC who underwent 18F-FDG PET/CT between Feburary 2009 and June 2017 at Osaka University Medical School Hospital for initial staging before surgery. We evaluated the association of MTV of primary tumor (T-MTV) with relapse-free survival (RFS) using Cox regression analysis. Receiver operating characteristic (ROC) curves were used to estimate the optimal cut-off values for T-MTV. We also conducted recursive partitioning analyses to offer a novel risk stratification system.
Results
The 3-year RFS for all patients were 81.2% with median follow-up of 42 months (range 11-111). In Cox model, T-MTV (Hazard Ratio, 1.23; 95% CI, 1.08 to 1.38; P = 0.002) was significantly associated with RFS. ROC analyses showed that the optimal cutoff value of T-MTV was 10.3ml. We classified the patients as having a low, intermediate, or high risk of relapse or death on the basis of T-MTV and lymph node metastasis.
Conclusions
MTV of primary tumor was a significant prognostic factor for RFS in patients with PTC treated with surgery. Incorporation of T-MTV into staging may lead to a better risk stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3353 - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Presenter: Jalid Sehouli
Session: Poster Display session 2
Resources:
Abstract
740 - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
Presenter: Alejandra Martinez de Pinillos
Session: Poster Display session 2
Resources:
Abstract
5867 - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Presenter: Robert Morgan
Session: Poster Display session 2
Resources:
Abstract
2966 - Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Presenter: Jihong Liu
Session: Poster Display session 2
Resources:
Abstract
1687 - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Presenter: Fernanda Milanezi
Session: Poster Display session 2
Resources:
Abstract
3162 - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
Presenter: Changbin Zhu
Session: Poster Display session 2
Resources:
Abstract
5993 - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital
Presenter: Begona Grana Suarez
Session: Poster Display session 2
Resources:
Abstract
5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status
Presenter: Angela George
Session: Poster Display session 2
Resources:
Abstract
4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Presenter: Michele Bartoletti
Session: Poster Display session 2
Resources:
Abstract
3251 - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Presenter: Fabrice Lecuru
Session: Poster Display session 2
Resources:
Abstract